Microneedle Delivery of Spray-Dried Microparticulate Vaccines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine delivery methods, such as subcutaneous and intramuscular injections, are invasive, painful, and require skilled professionals, while existing transdermal methods lack efficacy and convenience for cancer and infectious disease vaccinations.
Innovation Solution
Development of microneedle-mediated delivery of microparticulate vaccines, specifically using spray-dried microparticles containing whole cell lysates or antigens, administered through the skin to bypass nerve endings and enhance immune response, combined with adjuvants like IL-2 and IL-12 for improved immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If subcutaneous or intramuscular injection methods are used for vaccine delivery, then reliable immune response is achieved, but the procedure becomes invasive and painful requiring skilled professionals
Solution Approach 1:
The vaccine formulation is segmented into microparticulate form (1-100 micrometers) that can be delivered through microneedles, dividing the delivery system into penetrative needles and particulate vaccine carriers to achieve both reliable delivery and minimal invasiveness
Solution Approach 2:
Microneedles serve as an intermediary device that bridges the gap between non-invasive transdermal application and effective vaccine delivery, penetrating the stratum corneum to deposit microparticulate vaccines in the viable epidermis where immune cells are present
2Ease of operation
If transdermal delivery methods are used for vaccine administration, then ease of operation is improved, but delivery efficacy is insufficient
Solution Approach 1:
The microneedles are pre-formed and sterilized before use, and the vaccine is pre-formulated as microparticles, allowing for preliminary preparation that enables effective delivery through simple transdermal application without requiring skilled professionals during administration
Solution Approach 2:
The delivery system targets specific local qualities of the skin - the microneedles are designed to penetrate only the stratum corneum and deposit vaccine in the viable epidermis, creating localized high-concentration vaccine delivery at the application site to ensure efficacy
3Reliability
If microparticulate vaccines are delivered via microneedles, then immune response is enhanced, but formulation complexity increases
Solution Approach 1:
The vaccine formulation uses composite materials including biodegradable polymers (PLA, PGA, PLGA), natural polymers (chitosan, alginate), or synthetic polymers (Eudragit) combined with vaccine antigens and adjuvants to create microparticles that provide both structural integrity and controlled release properties for enhanced immune response
Solution Approach 2:
The formulation utilizes parameter changes in polymer properties (molecular weight, composition ratio, crystallinity) and microparticle characteristics (size, shape, surface charge) to control vaccine release kinetics and immune response magnitude, allowing optimization of immune activation while managing formulation complexity
Data Source
AI summary
A method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or beta-cyclodextrin, in an aqueous medium in a first vessel; contacting the dissolved polymer matrix with a crosslinking agent, such as glutaraldehyde, to crosslink the polymer matrix and the crosslinking agent; neutralizing with sodium bisulfate any excess crosslinking agent remaining after crosslinking is substantially complete; solubilizing in a second vessel a bioactive material in an aqueous solution; mixing the solubilized bioactive material together with the neutralized crosslinked polymer matrix in solution to form a mixture; and, spray drying the mixture to produce nanospheres, whereby substantial bioactivity of the biomaterial is retained upon cellular uptake.